EUVIMEDEUVIMED entdecken
Crossref

New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects

Frieda-Marie Bartz, Kinga Sałat, Katarzyna Urbańska, Jana Lemke iD, Pascal Rosendahl, Louis Schmidt iD, Lukas Schulig iD, Ulrike Garscha, Andreas Link iD, Patrick J Bednarski iD

ACS Chemical Neuroscience · 2025

DOI: 10.1021/acschemneuro.5c00278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Frieda-Marie Bartz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, University of Greifswald, Friedrich-Ludwig-Jahn-Str. 17, Greifswald 1748…. Hauptthemen laut MEDLINE: Analgesics, Aminopyridines, KCNQ2 Potassium Channel, KCNQ3 Potassium Channel. Die Arbeit nennt 71 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first-in-class KV7.2/3 channel activator flupirtine, was considered a potent analgesic in various pain conditions. However, it was withdrawn from the market in 2018 due to severe hepatotoxicity associated with forming reactive metabolites. In this work, we present new KV7.2/3 channel modulators that have been evaluated in several preclinical mouse pain models, including acute thermally and chemically induced pain, diabetes-induced neuropathic pain, and chemotherapy-induced peripheral neuropathy. In addition, the new KV7.2/3 channel activators were compared with the reference substances flupirtine, retigabine, and azetukalner, focusing on the inhibition of the hERG channel, nephrotoxicity, metabolic stability, and the formation of reactive metabolites. A flupirtine analog with a pyrimidine scaffold (8) showed clear advantages over the reference compounds tested, with a favorable toxicity profile, a 2 h in vitro half-life when incubated with human liver microsomes, and a 9-fold reduction in the formation of reactive metabolites compared to flupirtine. This compound also demonstrated strong in vivo efficacy in pain models, making it a promising candidate for further development of KV7.2/3 channel activators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnalgesicsAminopyridinesKCNQ2 Potassium ChannelKCNQ3 Potassium ChannelAnimalsMiceHumansMicrosomes, LiverMaleNeuralgiaPainDisease Models, AnimalCarbamatesPhenylenediamines

Stichwörter der Autor:innen

KV7.2/3analgesicsdrug developmentflupirtinehERGpain modelsreactive metabolites

Substanzen

flupirtineAnalgesicsAminopyridinesKCNQ2 Potassium ChannelKCNQ3 Potassium ChannelezogabineCarbamatesPhenylenediamines

Autor:innen und Institutionen

  • Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, University of Greifswald, Friedrich-Ludwig-Jahn-Str. 17, Greifswald 17489, Germany.
  • Faculty of Pharmacy, Chair of Pharmacodynamics, Jagiellonian University Medical College, 9 Medyczna St., Krakow 30-688, Poland.

ORCID-Profile: Jana Lemke, Louis Schmidt, Lukas Schulig, Andreas Link, Patrick J Bednarski

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Bartz, F. M., Sałat, K., Urbańska, K., Lemke, J., Rosendahl, P., Schmidt, L., Schulig, L., Garscha, U., Link, A., & Bednarski, P. J. (2025). New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00278

Vancouver

Bartz FM, Sałat K, Urbańska K, Lemke J, Rosendahl P, Schmidt L, et al. New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00278

BibTeX
@article{Bartz2025,
  author = {Bartz, Frieda-Marie and Sałat, Kinga and Urbańska, Katarzyna and Lemke, Jana and Rosendahl, Pascal and Schmidt, Louis and Schulig, Lukas and Garscha, Ulrike and Link, Andreas and Bednarski, Patrick J},
  title = {New K V 7.2/3 Channel Activators Exhibit Superior Toxicity and Metabolic Profiles to Flupirtine and Demonstrate Promising In Vivo Analgesic Effects},
  journal = {ACS Chemical Neuroscience},
  year = {2025},
  doi = {10.1021/acschemneuro.5c00278}
}
Kostenlos starten →